To determine whether RCAN1-422-32 mediates T cell cytotoxicity against GBM, we recalled RCAN1-422-32-primed T cells from different HLA-A24+ healthy donors (HDs) with HLA-A24+ GBM cells expressing RCAN1-4 at various levels (Fig. 3C; Supplementary Tables S3 and S4). The gene discussed is RCAN1; the disease is glioblastoma.